Rapport Therapeutics' Positron Emission Tomography Trial And Second Multiple Ascending Dose Trial For RAP-219, Demonstrated RAP-219 Achieved Target Receptor Occupancy Associated With Maximal Efficacy In Prior Preclinical Models Within Five Days Of...

Rapport Therapeutics的正電子發射斷層掃描試驗和第二次多次遞增劑量試驗顯示，RAP-219在五天內達到了與之前臨牀模型中最大療效相關的目標受體佔用率...

Benzinga · 01/09 20:06

Rapport Therapeutics' Positron Emission Tomography Trial And Second Multiple Ascending Dose Trial For RAP-219, Demonstrated RAP-219 Achieved Target Receptor Occupancy Associated With Maximal Efficacy In Prior Preclinical Models Within Five Days Of Dosing While Maintaining A Differentiated Tolerability Profile

Rapport Therapeutics的正電子發射斷層掃描試驗和第二次多次遞增劑量試驗顯示，RAP-219在給藥五天內達到了與先前臨牀前模型最大療效相關的目標受體佔用，同時保持了差異化的耐受性特徵。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。